Indications & Uses
Irita is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Colorectal cancer combination regimen 1: Irinotecan 125 mg/m2 intravenous infusion over 90 minutes on days 1, 8,15, 22 with LV 20 mg/m2 intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks.Colorectal cancer combination regimen 2: Irinotecan 180 mg/m2 intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m2 intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m 2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m 2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30.Colorectal cancer single agent regimen 1: Irinotecan 125 mg/m2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest.Colorectal cancer single agent regimen 2: Irinotecan 350 mg/m2 intravenous infusion over 90 minutes on day 1 every 3 weeks.
Side Effects
In clinical studies of irinotecan used in combination therapy, the following side effects were common, affecting more than 30% of patients: nausea, vomiting, abdominal pain, diarrhoea, constipation, loss of appetite, mucositis (inflammation of the lining of the mouth and gut), neutropenia, leukopenia (including lymphocytopenia), anaemia, thrombocytopenia, weakness, pain, fever, infection, abnormal bilirubin levels, and hair loss.
Cautions & Contraindications
Warnings & Precautions
Diarrhoea and cholinergic reactions: Early diarrhoea, which occurs during or shortly after an infusion of Irotecan, is usually short lived and rarely severe. It may come with cholinergic symptoms such as a runny nose, increased salivation, constricted pupils, watery eyes, sweating, flushing and overactive bowel movement that can cause abdominal cramping. A slow heart rate may also occur. Early diarrhoea and the other cholinergic symptoms can be prevented or treated. Consider giving 0.25 mg to 1 mg of atropine by intravenous or subcutaneous injection, either as prevention or as treatment, unless it is clinically contraindicated. These symptoms are expected to occur more often with higher doses of Irotecan. Late diarrhoea, which generally begins more than 24 hours after Irotecan is given, can be life threatening because it may be prolonged and may lead to dehydration, electrolyte imbalance or sepsis. Grade 3 to 4 late diarrhoea occurred in 23 to 31 percent of patients on weekly dosing. Myelosuppression: Deaths from sepsis following severe neutropenia have been reported in patients treated with Irotecan. In the clinical studies of the weekly dosing schedule, neutropenic fever (NCI grade 4 neutropenia together with fever of grade 2 or higher) occurred in 3 percent of patients, and 6 percent of patients received G-CSF to treat neutropenia. Febrile neutropenia should be managed promptly with antibiotic support. Patients with reduced UGT1A1 activity: People who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk of neutropenia after starting Irotecan treatment.
Contraindications
Irinotecan Injection must not be given to patients who are known to be hypersensitive to irinotecan or to any of the other ingredients in the preparation.